2550 Stanwell Drive
344 articles with Cerus Corporation
Cerus Corporation (Nasdaq:CERS) announced today a new corporate branding campaign building upon the Company’s leadership position in helping to safeguard the world’s blood supply and the planned relocation of its corporate offices to a new facility in Concord California.
Cerus’ INTERCEPT Blood System Provides Alternative to Year-Round Babesia Testing in Latest FDA Guidance Document
In 15 Babesiosis endemic states, treating donated blood components with the INTERCEPT Blood System is a recognized alternative to year-round Babesia testing using a DNA-based test.
First quarter ended March 31, 2019.
The company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
Cerus Corporation announced the closing of a new debt facility with MidCap Financial which is expandable up to $90 million.
Cerus Corporation announced the appointment of Jami Nachtsheim to its Board of Directors. Ms. Nachtsheim currently serves on the Board at Intuitive Surgical, the global market leader in robotic-assisted minimally invasive surgical systems.
Cerus Corporation (Nasdaq: CERS) today announced complete financial results for the fourth quarter and year ended December 31, 2018.
Cerus Corporation announced that the Company will participate in two upcoming investor conferences.
Cerus Corporation (Nasdaq:CERS) announced today that its fourth quarter and full-year 2018 results will be released on Tuesday, February 26, 2019, after the close of the stock market.
2019 product revenue guidance of $70 million to $73 million, representing growth of 15% to 20% over preliminary 2018 results
Cerus Corporation (Nasdaq:CERS) today announced the initiation and first patient enrollment in ReCePI, a randomized, double-blinded, controlled, parallel group, non-inferiority, Phase 3 study to evaluate the efficacy and safety of the INTERCEPT Blood System for red blood cells in patients undergoing complex cardiac surgery procedures.
Cerus today announced that it has filed for CE Mark registration for the Company’s INTERCEPT red blood cell system.
Cerus Corporation (Nasdaq:CERS) announced today the issuance of a new U.S. Food and Drug Administration (FDA) draft guidance document on bacterial risk control strategies for platelet collection and transfusion.
Cerus Corporation (Nasdaq:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Vivek Jayaraman, Cerus’ chief commercial officer, are scheduled to present a corporate update at the 2018 Canaccord Genuity Medical Technologies and Diagnostics Forum at 1:30 p.m. ET on Thursday, November 15, 2018.
Cerus Corporation (Nasdaq:CERS) announced today that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, and Kevin Green, Cerus’ vice president, finance and chief financial officer, are scheduled to present a corporate update at the 2018 Stephens NY Investment Conference
Cerus Corporation announced today financial results for the third quarter ended September 30, 2018.
The basis of the designation is improved treatment of massive hemorrhage, a life-threatening medical condition.
Cerus Corporation (Nasdaq:CERS) announced today that its third quarter results will be released on Thursday, November 1, 2018, after the close of the stock market.
Cerus to Provide Update to Development Programs and Outline Growth Strategy at 2018 Institutional Investor Meeting
Cerus Corporation (Nasdaq: CERS) is presenting its strategic roadmap and outlining its multi-year growth strategy at the 2018 Cerus Institutional Investor Meeting today in Boston.
Company’s co-founder and chief scientific officer has been awarded the prestigious Dale A. Smith Memorial Award by AABB’s National Blood Foundation.